Trial Profile
Phase II trial of pembrolizumab as first-line therapy for advanced non-small cell lung cancer with high PD-L1 expression in patients with poor performance status 1801
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2018
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 09 Nov 2018 New trial record